CD19 and diffuse large B-cell lymphoma: In the cell collection stage, patients with diffuse large B-cell lymphoma (DLBCL) who are non-responsive to anti-CD19 CAR-T cell therapy exhibit a higher proportion of CD28-CD27-CD3 T cells in leukapheresis samples298.